Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8488724 | 0.71 | TRPV4 (0.37) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL9911978 | 0.71 | PTGS2 (0.40) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL2374152 | 0.71 | HSP90AA1 (0.38) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL31698519 | 0.71 | CES1 (0.33) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL14602878 | 0.68 | IDH1 (0.32) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL31532409 | 0.67 | CES1 (0.36) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL3250812 | 0.67 | CES1 (0.33) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL13341092 | 0.67 | CYP3A4 (0.38) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL14641210 | 0.67 | PDE4B (0.36) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL7634551 | 0.67 | CES1 (0.36) | CES1NCEH1DAGLACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119677733-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3057963-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | Boehringer Ingelheim International GmbH (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015055698-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | SLC6A7, SLC7A11, SLC7A1 | CES1 618/4885NCEH1 1749/4885DAGLA 3958/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | CES1 747/4885NCEH1 674/4885DAGLA 230/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | CES1 718/4885NCEH1 2192/4885DAGLA 3859/4885 |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | CES1 3664/4885NCEH1 2996/4885DAGLA 4746/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | CES1 2402/4885NCEH1 2932/4885DAGLA 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.